J. Schmit

发表

European recommendations for the clinical use of HIV drug resistance testing: 2011 update.

M. Poljak, F. Ceccherini‐Silberstein, R. Paredes, 2011, AIDS reviews.

Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients

Pieter J. K. Libin, M. Poljak, A. Wensing, 2012, Retrovirology.

Rescue of HIV-1 long-time archived X4 strains to escape maraviroc.

D. Struck, V. Arendt, J. Schmit, 2011, Antiviral research.

Associations between antimicrobial susceptibility/resistance of Neisseria gonorrhoeae isolates in European Union/European Economic Area and patients’ gender, sexual orientation and anatomical site of infection, 2009–2016

J. Mossong, V. Miriagou, M. Unemo, 2021, BMC Infectious Diseases.

HIV-1 Tropism Determination Using a Phenotypic Env Recombinant Viral Assay Highlights Overestimation of CXCR4-Usage by Genotypic Prediction Algorithms for CRRF01_AE and CRF02_AG

D. Struck, Eveline Santos da Silva, C. Verhofstede, 2013, PloS one.

Prevalence of hepatitis B and C and HIV infections among problem drug users in Luxembourg: self-report versus serological evidence

J. Schmit, Alain Origer, 2010, Journal of Epidemiology & Community Health.

Isolation of an HIV-1 neutralizing peptide mimicking the CXCR4 and CCR5 surface from the heavy-chain complementary determining region 3 repertoire of a viremic controller

J. Schmit, A. Rybicki, C. Seguin-Devaux, 2016, AIDS.

Structure prediction of GPCRs using piecewise homologs and application to the human CCR5 chemokine receptor: validation through agonist and antagonist docking

K. Arumugam, J. Schmit, C. Seguin-Devaux, 2014, Journal of biomolecular structure & dynamics.

Phages and HIV-1: From Display to Interplay

J. Schmit, A. Chevigné, S. Delhalle, 2012, International journal of molecular sciences.

Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations.

E. De Clercq, T. Harrer, M. Van Ranst, 1999, Journal of Acquired Immune Deficiency Syndromes.

Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain.

E. De Clercq, A. Vandamme, J. Balzarini, 1996, The Journal of infectious diseases.

Correction: HIV-1 Tropism Determination Using a Phenotypic Env Recombinant Viral Assay Highlights Overestimation of CXCR4-Usage by Genotypic Prediction Algorithms for CRRF01_AE and CRF02_AG

D. Struck, Eveline Santos da Silva, C. Verhofstede, 2013, PLoS ONE.

Function, diversity and therapeutic potential of the N-terminal domain of human chemokine receptors.

N. V. van Nuland, J. Schmit, V. Fiévez, 2012, Biochemical pharmacology.

Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: Analysis of the HIV-2 Belgium and Luxembourg database

K. Van Laethem, C. Verhofstede, J. Schmit, 2008, BMC infectious diseases.

An individualized functional magnetic resonance imaging protocol to assess semantic congruency effects on episodic memory in an aging multilingual population

G. Fink, S. Viswanathan, L. Huiart, 2022, Frontiers in Aging Neuroscience.

A hepatitis A, B, C and HIV prevalence and risk factor study in ever injecting and non-injecting drug users in Luxembourg associated with HAV and HBV immunisations

M. Vaillant, J. Schmit, Alain Origer, 2011, BMC public health.

Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir

A. Ternes, J. Schmit, S. Dao, 2010, Retrovirology.

Uncommon mutations at residue positions critical for enfuvirtide (T-20) resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains.

V. Arendt, J. Schmit, R. Boulmé, 2003, Journal of acquired immune deficiency syndromes.

A new recombinant virus system for the study of HIV-1 entry and inhibition.

C. Muller, W. Ammerlaan, V. Arendt, 2006, Journal of virological methods.

The HIV/AIDS epidemic in sub-Saharan Africa: thinking ahead on programmatic tasks and related operational research

A. Harries, R. Zachariah, V. Arendt, 2011, Journal of the International AIDS Society.

High correlation between the Roche COBAS® AmpliPrep/COBAS® TaqMan® HIV-1, v2.0 and the Abbott m2000 RealTime HIV-1 assays for quantification of viral load in HIV-1 B and non-B subtypes.

G. Colucci, U. Reischl, J. Schmit, 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

HIV-1 subtypes in Luxembourg, 1983–2000

V. Arendt, J. Schmit, F. Schneider, 2002, AIDS.

A novel 24-base pair deletion in the coding region of CCR5 in an African population.

E. Karita, S. Allen, V. Arendt, 2007, AIDS.

Fast genotypic detection of drug resistance mutations in the HIV-1 reverse transcriptase gene of treatment-naive patients.

V. Arendt, J. Schmit, J. Servais, 1998, Journal of human virology.

Associations Between Wearable-Specific Indicators of Physical Activity Behaviour and Insulin Sensitivity and Glycated Haemoglobin in the General Population: Results from the ORISCAV-LUX 2 Study

A. Alkerwi, Y. Devaux, L. Huiart, 2022, Sports medicine - open.

Antiviral efficacy and resistance in patients on antiretroviral therapy in Kigali, Rwanda: the real‐life situation in 2002

V. Arendt, J. Schmit, J. Ende, 2006, HIV medicine.

SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus

E. De Clercq, C. Pannecouque, A. Vandamme, 1997, Antimicrobial agents and chemotherapy.

Chemical Constituents of Cassia abbreviata and Their Anti-HIV-1 Activity

A. Steinmetz, J. Schmit, Xianwen Yang, 2021, Molecules.

Active Components from Cassia abbreviata Prevent HIV-1 Entry by Distinct Mechanisms of Action

A. Steinmetz, M. Mori, D. Schols, 2021, International journal of molecular sciences.

Penicilliosis marneffei infection in AIDS.

J. Saurat, L. Borradori, J. Schmit, 1994, Journal of the American Academy of Dermatology.

HIV‐Associated Hematologic Disorders Are Correlated With Plasma Viral Load and Improve Under Highly Active Antiretroviral Therapy

M. Moutschen, V. Arendt, J. Schmit, 2001, Journal of acquired immune deficiency syndromes.

The global spread of HIV-1 subtype B epidemic

M. Poljak, A. Wensing, R. Paredes, 2016, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

Simultaneous quantification of zidovudine, stavudine, lamivudine and nevirapine by Micellar Electrokinetic Capillary Chromatography

J. Schmit, M. Yegles, S. Schneider, 2012 .

Presence of 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxath iole-2",2"-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patients.

R. Esnouf, E. De Clercq, B. Clotet, 2000, AIDS research and human retroviruses.

Updated European Recommendations for the Clinical Use of HIV Drug Resistance Testing

JD Lundgren, N Clumeck, A. D. Luca, 2004, Antiviral therapy.

Hepatitis C virus genotypes distribution and transmission risk factors in Luxembourg from 1991 to 2006.

D. Struck, A. Ternes, V. Arendt, 2008, World journal of gastroenterology.

Clinical Evaluation of Rega 8: An Updated Genotypic Interpretation System That Significantly Predicts HIV-Therapy Response

Rolf Kaiser, Anne-Mieke Vandamme, Stijn Imbrechts, 2013, PloS one.

1,1,3-Trioxo-2H,4H-Thieno[3,4-e][1,2,4]Thiadiazine (TTD) Derivatives: a New Class of Nonnucleoside Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase Inhibitors with Anti-HIV-1 Activity

R. Esnouf, E. De Clercq, C. Pannecouque, 1998, Antimicrobial Agents and Chemotherapy.

Prevalence and Characteristics of Multinucleoside-Resistant Human Immunodeficiency Virus Type 1 among European Patients Receiving Combinations of Nucleoside Analogues

E. De Clercq, C. Pannecouque, B. Clotet, 2000, Antimicrobial Agents and Chemotherapy.

The Calculated Genetic Barrier for Antiretroviral Drug Resistance Substitutions Is Largely Similar for Different HIV-1 Subtypes

Klaus Korn, Anne-Mieke Vandamme, Sabine Yerly, 2006, Journal of acquired immune deficiency syndromes.

Evaluation of saliva as an alternative matrix for monitoring plasma Zidovudine, Lamivudine and nevirapine concentrations in Rwanda.

N. Sauvageot, A. Ternes, V. Arendt, 2011, Current HIV research.

COMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification

Glenn Lawyer, Daniel Struck, Jean-Claude Schmit, 2014, Nucleic acids research.

Antiviral activity of the bicyclam derivative JM3100 against drug-resistant strains of human immunodeficiency virus type 1.

E. De Clercq, A. Vandamme, M. Witvrouw, 1996, Antiviral research.

Viral load and CD4 cell response to protease inhibitor-containing regimens in subtype B versus non-B treatment-naive HIV-1 patients

N. Clumeck, S. De Wit, J. Schmit, 2004, AIDS.

Quantification of HIV-1 RNA in plasma: comparable results with the NASBA HIV-1 RNA QT and the AMPLICOR HIV monitor test.

E. De Clercq, A. Vandamme, S. Van Dooren, 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

The Envelope Cytoplasmic Tail of HIV-1 Subtype C Contributes to Poor Replication Capacity through Low Viral Infectivity and Cell-to-Cell Transmission

J. Schmit, Morgane Lemaire, J. Servais, 2016, PloS one.

Hypertension burden in Luxembourg

S. Stranges, N. Kandala, C. Delagardelle, 2016, Medicine.

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe

Jan Albert, Kirsi Liitsola, Mario Poljak, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Global Dispersal Pattern of HIV Type 1 Subtype CRF01_AE: A Genetic Trace of Human Mobility Related to Heterosexual Sexual Activities Centralized in Southeast Asia.

M. Poljak, A. Wensing, R. Paredes, 2015, The Journal of infectious diseases.

Near Full-Length Characterization and Population Dynamics of the Human Immunodeficiency Virus Type I Circulating Recombinant Form 42 (CRF42_BF) in Luxembourg.

D. Struck, J. Schmit, M. Nijhuis, 2015, AIDS research and human retroviruses.

Phase I/II dose escalation and randomized withdrawal study with add-on azodicarbonamide in patients failing on current antiretroviral therapy

C. Pannecouque, F. Goebel, E. Clercq, 2001, AIDS.

SRR-SB 3 , a Disulfide-Containing Macrolide That Inhibits a Late Stage of the Replicative Cycle of Human Immunodeficiency Virus

C. Pannecouque, A. Vandamme, J. Balzarini, 1997 .

Simple DNA Extraction Method for Dried Blood Spots and Comparison of Two PCR Assays for Diagnosis of Vertical Human Immunodeficiency Virus Type 1 Transmission in Rwanda

V. Arendt, J. Schmit, J. Servais, 2004, Journal of Clinical Microbiology.

Detection of HIV-1 RNA in plasma and serum samples using the NASBA amplification system compared to RNA-PCR.

E. De Clercq, A. Vandamme, S. Van Dooren, 1995, Journal of virological methods.

Cell type-dependent effect of sodium valproate on human immunodeficiency virus type 1 replication in vitro.

E. De Clercq, A. Vandamme, M. Witvrouw, 1997, AIDS research and human retroviruses.

Automated sequence analysis and editing software for HIV drug resistance testing.

T. F. Rinke de Wit, Gennady Denisov, D. Struck, 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

European surveillance of ICU-acquired infections (HELICS-ICU): methods and main results.

A Lepape, M Hiesmayr, P Gastmeier, 2007, The Journal of hospital infection.

Transmission of drug-resistance in Europe is characterized by single mutations and revertants

A. Wensing, K. Korn, G. Poggensee, 2006 .

Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management.

Klaus Korn, Anne-Mieke Vandamme, Sabine Yerly, 2005, The Journal of infectious diseases.

Engineering and screening the N-terminus of chemokines for drug discovery.

J. Schmit, V. Fiévez, A. Chevigné, 2011, Biochemical pharmacology.

Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach

O. Pybus, A. Wensing, K. Korn, 2009, Retrovirology.

Recent advances in antiretroviral therapy and HIV infection monitoring.

J. Schmit, B. Weber, 1997, Intervirology.

Transmission of drug-resistant HIV-1 is stabilizing in Europe.

M. Poljak, A. Wensing, K. Korn, 2009, The Journal of infectious diseases.

HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics

Klaus Korn, Kristof Theys, Anne-Mieke Vandamme, 2013, Retrovirology.

Patterns of Transmitted HIV Drug Resistance in Europe Vary by Risk Group

M. Poljak, R. Paredes, K. Korn, 2014, PloS one.

Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting

K. Hertogs, F. Brun-Vézinet, D. Pillay, 2001 .

Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGUidelines Group for HIV resistance.

Soriano, K. Hertogs, F. Brun-Vézinet, 2001, AIDS.

HIV type 1 pol gene diversity and archived nevirapine resistance mutation in pregnant women in Rwanda.

E. Karita, V. Arendt, J. Schmit, 2004, AIDS research and human retroviruses.

Evaluating Clinical Isolates for Their Phenotypic and Genotypic Resistance Against Anti-HIV Drugs.

J Desmyter, E. De Clercq, C. Pannecouque, 2000, Methods in molecular medicine.

Laboratory Guidelines for the Practical Use of HIV Drug Resistance Tests in Patient Follow-Up

K. Hertogs, B. Larder, B. Clotet, 2001, Antiviral therapy.

Baseline HIV type 1 genotypic resistance to a newly added nucleoside analog is predictive of virologic failure of the new therapy.

E. De Clercq, B. Clotet, L. Ruiz, 2000, AIDS research and human retroviruses.

Prevalence of HIV co-receptor polymorphisms in HIV-infected patients and uninfected volunteers in Luxembourg

J. Mossong, J. Schmit, J. Servais, 2002, HIV clinical trials.

Transmission of HIV-1 Drug Resistance

A. Wensing, J. Schmit, L. Hofstra, 2015 .

Neutralising properties of peptides derived from CXCR4 extracellular loops towards CXCL12 binding and HIV-1 infection.

J. Schmit, V. Fiévez, M. Szpakowska, 2014, Biochimica et biophysica acta.

Predominance of the heterozygous CCR5 delta‐24 deletion in African individuals resistant to HIV infection might be related to a defect in CCR5 addressing at the cell surface

E. Karita, S. Allen, V. Arendt, 2019, Journal of the International AIDS Society.

Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotype

R. Esnouf, E. De Clercq, C. Pannecouque, 2001, AIDS.

Is the Vpr R77Q mutation associated with long-term non-progression of HIV infection?

E. Karita, S. Allen, V. Arendt, 2004, AIDS.

ADA, a potential anti-HIV drug.

E. De Clercq, M. Witvrouw, J. Schmit, 1996, AIDS research and human retroviruses.

Multidrug resistant human immunodeficiency virus type I

A. Vandamme, J. Schmit, K. V. Vaerenbergh, 2000 .

Evolution of HIV drug Resistance in Zidovudine/Zalcitabine- and Zidovudine/ Didanosine-Experienced Patients Receiving Lamivudine-Containing Combination Therapy

E. De Clercq, B. Clotet, J. Martinez-Picado, 1998 .

Longitudinal use of phenotypic resistance testing to HIV‐1 protease inhibitors in patients developing HAART failure

V. Arendt, J. Schmit, J. Servais, 2002, Journal of medical virology.

Comparison of DNA Sequencing and a Line Probe Assay for Detection of Human Immunodeficiency Virus Type 1 Drug Resistance Mutations in Patients Failing Highly Active Antiretroviral Therapy

Guy Burtonboy, Jean-Claude Schmit, V. Arendt, 2001, Journal of Clinical Microbiology.

Longitudinal Use of a Line Probe Assay for Human Immunodeficiency Virus Type 1 Protease Predicts Phenotypic Resistance and Clinical Progression in Patients Failing Highly Active Antiretroviral Therapy

V. Arendt, J. Schmit, J. Servais, 2002, Antimicrobial Agents and Chemotherapy.

Highly Active Antiretroviral Therapy and Clinical Progression in Patients Failing Protease Predicts Phenotypic Resistance Human Immunodeficiency Virus Type 1 Longitudinal Use of a Line Probe Assay for

V. Arendt, J. Schmit, J. Servais, 2002 .

Impact on Replicative Fitness of the G48E Substitution in the Protease of HIV-1: An In Vitro and In Silico Evaluation

A. Vandamme, K. Van Laethem, M. de Maeyer, 2008, Journal of acquired immune deficiency syndromes.

E. De Clercq, B. Clotet, J. Leonard, 1996, AIDS.

Creation of a federated database of blood proteins: a powerful new tool for finding and characterizing biomarkers in serum

Fay Betsou, John Marshall, Peter Bowden, 2014, Clinical Proteomics.

Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe

M. Poljak, A. Wensing, R. Paredes, 2014, BMC Infectious Diseases.

Initiation of HAART in drug-naive HIV type 1 patients prevents viral breakthrough for a median period of 35.5 months in 60% of the patients.

E. De Clercq, B. Schmidt, H. Walter, 2002, AIDS research and human retroviruses.

Resistance testing in children changing human immunodeficiency virus type 1 protease inhibitor

V. Arendt, J. Schmit, K. Fransen, 2002, The Pediatric infectious disease journal.

Variant Human Immunodeficiency Virus Type 1 Proteases and Response to Combination Therapy Including a Protease Inhibitor

Guy Burtonboy, Jean-Claude Schmit, V. Arendt, 2001, Antimicrobial Agents and Chemotherapy.

Three-Year Effectiveness of Highly Active Antiretroviral Treatment in the Luxembourg HIV Cohort

V. Arendt, J. Schmit, J. Servais, 2000, HIV clinical trials.

An individualized fMRI-based protocol to assess semantic memory in a heterogeneous multilingual population

G. Fink, S. Viswanathan, L. Huiart, 2021 .

Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC

B. Clotet, J. Martinez-Picado, L. Ruiz, 1996, AIDS.

Original article / Article original Simultaneous quantification of zidovudine, stavudine, lamivudine and nevirapine by Micellar Electrokinetic Capillary Chromatography Quantification simultanée de zidovudine, stavudine, lamivudine et névirapine par chromatographie électrocinétique micellaire

J. Schmit, M. Yegles, S. Schneider, 2013 .

Evaluation of two commercial kits for the detection of genotypic drug resistance on a panel of HIV type 1 subtypes A through J.

E. De Clercq, M. Van Ranst, M. Peeters, 2001, Journal of acquired immune deficiency syndromes.

Viraemia and HIV-1 drug resistance mutations among patients receiving antiretroviral treatment in Mozambique.

R. Zachariah, V. Arendt, J. Schmit, 2009, Transactions of the Royal Society of Tropical Medicine and Hygiene.

Efficacy of tenofovir and efavirenz in combination with lamivudine or emtricitabine in antiretroviral-naive patients in Europe.

A. Wensing, R. Paredes, R. Kaiser, 2015, The Journal of antimicrobial chemotherapy.

Limited cross-border infections in patients newly diagnosed with HIV in Europe

M. Poljak, A. Wensing, R. Paredes, 2013, Retrovirology.

Genotypic Correlates of Resistance to HIV-1 Protease Inhibitors on Longitudinal Data: The Role of Secondary Mutations

V. Arendt, J. Schmit, J. Servais, 2000, Antiviral therapy.

Rare and new V3 loop variants in HIV-1-positive long-term non-progressors from Rwanda.

E. Karita, S. Allen, V. Arendt, 2002, AIDS.

Indinavir hair concentration in highly active antiretroviral therapy-treated patients: association with viral load and drug resistance.

G. Peytavin, V. Arendt, J. Schmit, 2001, AIDS.

Device-measured physical activity and sedentary time in a national sample of Luxembourg residents: the ORISCAV-LUX 2 study

A. Alkerwi, Y. Devaux, L. Huiart, 2022, International Journal of Behavioral Nutrition and Physical Activity.

Creation of a federated database of blood proteins: a powerful new tool for finding and characterizing biomarkers in serum

F. Betsou, J. Schmit, Peter Bowden, 2014, Clinical Proteomics.

Patient HIV-1 strains carrying the multiple nucleoside resistance mutations are cross-resistant to abacavir.

E. De Clercq, T. Harrer, B. Clotet, 2000, AIDS.

Virologic therapy response significantly correlates with the number of active drugs as evaluated using a LiPA HIV-1 resistance scoring system.

A. Vandamme, G. Zissis, K. Van Laethem, 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patients

F. Clavel, P. Clevenbergh, J. Schmit, 2002, HIV clinical trials.

Long-Term Virological Outcome in Patients Infected with Multi-Nucleoside Analogue-Resistant HIV-1

M. Dupon, P. Clevenbergh, J. Schmit, 2001, Antiviral Therapy.

Multiple dideoxynucleoside analogue‐resistant (MddNR) HIV‐1 strains isolated from patients from different European countries

T. Harrer, B. Clotet, L. Ruiz, 1998, AIDS.

Association of diet quality indices with serum and metabolic biomarkers in participants of the ORISCAV-LUX-2 study

A. Alkerwi, Y. Devaux, L. Huiart, 2023, European Journal of Nutrition.

Non-immunized natural human heavy chain CDR3 repertoires allow the isolation of high affinity peptides mimicking a human influenza hemagglutinin epitope.

I. Lasters, N. Boutonnet, H. de Haard, 2008, Molecular immunology.

A direct comparison of drug susceptibility to HIV type 1 from antiretroviral experienced subjects as assessed by the antivirogram and PhenoSense assays and by seven resistance algorithms.

J. Schmit, R. Boulmé, A. Florance, 2005, AIDS research and human retroviruses.